A5082039225- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Eosinophilic Esophagitis
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Celiac Disease Research and Management
- Liver Diseases and Immunity
- Autoimmune and Inflammatory Disorders
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal disorders and treatments
- Digestive system and related health
- COVID-19 and healthcare impacts
- Intestinal and Peritoneal Adhesions
- Mycobacterium research and diagnosis
- Abdominal vascular conditions and treatments
- Pancreatitis Pathology and Treatment
- Gastroesophageal reflux and treatments
- Colorectal Cancer Treatments and Studies
- Gastrointestinal motility and disorders
- Adipokines, Inflammation, and Metabolic Diseases
- Nuclear Structure and Function
- Dental Research and COVID-19
Takeda (Japan)
2025
Takeda (United States)
2020-2024
Janssen (Belgium)
2023
AbbVie (United States)
2023
Abbott Nutrition (United States)
2023
Deerfield (United States)
2020
University of Massachusetts Chan Medical School
2013-2017
UMass Memorial Health Care
2016
UMass Memorial Medical Center
2016
Cohen Children's Medical Center
2013
Non-synonymous mutations affecting both alleles of PCSK1 (proprotein convertase 1/3) are associated with obesity and impaired prohormone processing. We report a proband who was compound heterozygous for maternally inherited frameshift mutation paternally 474kb deletion that encompasses PCSK1, representing novel genetic mechanism underlying this phenotype. Although pro-vasopressin is not known physiological substrate the development central diabetes insipidus in suggests deficiency can be...
Abstract Background In randomized placebo-controlled trials (RCTs) for ulcerative colitis (UC), remission rates below 40% (wk52). Landmark analyses using independent endpoints provide approvable estimands overall efficacy but overlook individual variability.Notably, a subset of patients achieves deeper levels. Post hoc analysis the SELECTION trial (filgotinib) demonstrated that treating daily PRO2 scores (stool frequency, rectal bleeding) as time-series data reveals discrete...
Biologic medications are recommended for treatment of moderately-to-severely active Crohn disease (CD) or ulcerative colitis (UC) in children. However, many patients require sequential biologic because nonresponse loss response to the initial biologic.We analyzed pediatric inflammatory bowel (IBD) data from ImproveCareNow Network registry between May 2006 and September 2016, including time initiation, choice first subsequent biologics, durability, reasons discontinuation.Of 17,649 with IBD...
Importance Irritable bowel syndrome (IBS) is associated with significant morbidity in children and adolescents, the therapeutic efficacy of available treatment options limited. The role vitamin D supplementation pediatric IBS unclear as status patients unknown. Equally, relationship psychosomatic symptoms adolescents unclear. Aim To characterize using a case-control study design. Hypothesis Serum 25-hydroxyvitamin [25(OH)D] concentration will be similar between controls. Subjects methods A...
Patients with inflammatory bowel disease (IBD) may receive multiple successive biologic treatments in clinical practice; however, data are limited on the comparative effectiveness of biologics and impact treatment sequence outcomes.
The impact of the COVID-19 pandemic on patients with inflammatory bowel disease [IBD] is largely unknown. We characterised IBD care by conducting an analysis US health claims data. obtained de-identified, open-source, insurance data, from January 2019 to December 2020, Symphony Health Integrated Dataverse for adults IBD, and measured rates per 1000 five outcomes: colonoscopies; new biologic or small molecule treatment initiations switches; switches in who had a colonoscopy within previous 60...
Abstract Background Vedolizumab, an anti-α4β7 integrin approved for intravenous (IV) treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), was evaluated as a subcutaneous (SC) formulation in maintenance therapy UC CD phase 3 VISIBLE 1, 2, open-label extension studies, recently Europe, Australia, Canada. Our aim evaluate efficacy safety IV SC vedolizumab clinically relevant scenarios. Methods Post hoc data analyses from trials examined: (1) whether...
Background The health consequences of lactose intolerance (LI) are unclear. Aims To investigate the effects LI on stature and vitamin D status. Hypotheses subjects will have similar heights status as controls. Subjects Methods Prepubertal children ages 3-12 years with (n=38, age 8.61 ± 3.08y, male/female 19/19) were compared to healthy, age- gender-matched controls (n=49, 7.95±2.64, 28/21). Inclusion criteria: prepubertal (boys: testicular volume <3cc; girls: Tanner 1 breasts), diagnosis by...
Crohn's disease (CD) is a chronic inflammatory bowel characterized by relapsing and remitting inflammation that leads to progressive damage. Despite advances in medical treatment for CD, many patients require surgical intervention. Most studies of surgery rates are from treated with anti-tumor necrosis factor alpha (anti-TNFα) treatments, comparatively little data on the vedolizumab ustekinumab. SOJOURN aimed estimate hazard rate incidence first CD-related following initiation or ustekinumab...
Objective To compare real-world treatment persistence, dose escalation, rates of opportunistic or serious infections, and healthcare costs in patients with Crohn's disease (CD) receiving vedolizumab (VDZ) vs ustekinumab (UST) the United States.
Abstract Background Patients with ulcerative colitis (UC) typically receive a targeted inflammatory bowel disease therapy after treatment conventional therapies and the development of significant morbidity. Evidence suggests that early biologic diagnosis could improve response prevent complications compared delayed therapy. Methods RALEE was retrospective study using claims data from IBM® MarketScan® Research Databases between January 1, 2016 December 31, 2019. Adults UC at least one claim...
Dose escalation of biologics may regain treatment response in patients with ulcerative colitis (UC). However, dose rates and associated outcomes costs are not well characterized biologic-naïve receiving antitumor necrosis factor-alpha (anti-TNF-α) treatments, such as infliximab or adalimumab vedolizumab.ODESSA-UC, a retrospective cohort study investigating UC who had received first-line biologics, used data from IBM MarketScan databases. Adults ≥1 claim for an index drug (adalimumab,...
Patients with Crohn's disease (CD) are at risk of complications. Performance characteristics a decision support tool assessing the CD complications were evaluated.CDPATH (formerly called Personalized Risk and Outcome Prediction Tool [PROSPECT]) was calibrated validated in 2 cohorts. prediction assessed using Cox regression Harrell's C-statistic.All associations CDPATH components significant except perianal location. There association between individualized assessment scores both...
Individuals with Down syndrome (DS) have an increased prevalence of autoimmune disorders, reported rates 3% to 54% for thyroid disorders and 5% 20% celiac disease (CD) (1–3). CD can present extraintestinal manifestations such as poor growth, osteoporosis, neuropsychiatric manifestations, delayed puberty, infertility, menstrual irregularities (4,5). We describe adolescent girl DS Graves presenting polymenorrhea the initial symptom CD. CASE PRESENTATION A 7-year-old presented a 2-month history...
Determining the relative cost-effectiveness between advanced therapeutic options for ulcerative colitis (UC) may optimize resource utilization. We evaluated total cost per response, remission, and of safety events patients with moderately-to-severely active UC after 52 weeks treatment therapies at standard dosing.An analytic model was developed to estimate costs from US healthcare system perspective associated achieving efficacy outcomes managing approved UC. Numbers needed treat (NNT)...
Splenic artery pseudoaneurysm (SAP) formation is an uncommon complication of pancreatitis. It believed to be the result vascular erosion by pancreatic enzymes, a process that compromises integrity splenic wall. The final weak, expanded vessel wall may hemorrhage into peritoneal cavity or retroperitoneal space (1). There are no known reports SAP in pediatric population patients with hereditary We report case 5-year-old child pancreatitis was successfully managed via transcatheter coil...
Dose escalation of biologics may restore response in patients with Crohn's disease (CD) who experience inadequate or loss response, but the rates dose and subsequent adverse clinical outcomes have not been well characterized.
Abstract Background Vedolizumab (VDZ), a gut-selective, α 4β7 integrin monoclonal antibody, is approved for intravenous (IV) administration to patients with moderate-severe ulcerative colitis (UC). Subcutaneous (SC) VDZ was evaluated maintenance therapy UC in VISIBLE 1, double-blind, placebo-controlled, Phase 3 study, and its open-label extension (OLE). We the efficacy of increasing dose frequency SC from every-2-weeks (Q2W) weekly (QW) after treatment failure (disease worsening or need...
Abstract BACKGROUND In the real-world clinical setting, patients with moderate-to-severe ulcerative colitis (UC) may undergo dose escalation when they lose response to their prescribed biologic treatment. Such of agents has an impact on healthcare utilization and costs have patient outcomes. Currently, limited data exist that compare rates between anti-tumor necrosis factor (anti-TNF) therapies vedolizumab, a gut-selective integrin antagonist, in UC who not previously been treated (bio-naïve...
Abstract INTRODUCTION Following inadequate response, loss of or intolerance to a first-line biologic, patients with Crohn’s disease (CD) may switch treatment second-line biologic therapy. Data on the clinical outcomes receiving two more lines therapy are limited. We assessed adverse CD different sequences. METHODS ROTARY (Real-wOrld ouTcomes Across tReatment sequences in inflammatorY bowel patients) part B used data from Optum Clinical Database and included adult diagnosed who received at...